Compounds > carteolol

carteolol and labetalol

carteolol has been researched along with labetalol in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (25.00)18.2507
2000's3 (37.50)29.6817
2010's2 (25.00)24.3611
2020's1 (12.50)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Baba, T; Takebe, K; Tomiyama, T1
Baba, T; Murabayashi, S; Takebe, K; Tomiyama, T1
Carlo, MJ; Patrick, AL1

Trials

2 trial(s) available for carteolol and labetalol

ArticleYear
Metabolic effects of carteolol and dilevalol in essential hypertension.
    European journal of clinical pharmacology, 1992, Volume: 42, Issue:1

    Topics: Carteolol; Humans; Hypertension; Labetalol

1992
Comparison of the renal effects of dilevalol and carteolol in patients with mild to moderate essential hypertension.
    European journal of clinical pharmacology, 1990, Volume: 38, Issue:3

    Topics: Adult; Aldosterone; Blood Proteins; Carteolol; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Hypertension; Kidney; Kidney Function Tests; Labetalol; Male; Middle Aged; Propanolamines; Randomized Controlled Trials as Topic; Renal Circulation; Renin

1990

Other Studies

6 other study(ies) available for carteolol and labetalol

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
    Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21

    Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship

2008
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
    Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6

    Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics

2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Further exploration of the collision-induced dissociation of select beta blockers: Acebutolol, atenolol, bisoprolol, carteolol, and labetalol.
    Journal of mass spectrometry : JMS, 2023, Volume: 58, Issue:12

    Topics: Acebutolol; Atenolol; Bisoprolol; Carteolol; Chromatography, Liquid; Labetalol; Tandem Mass Spectrometry

2023